The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism
The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. A need exists for a therapy that lowers parathyroid hormone (PTH) without increasing calcium x phosphorus in patients with secondary hyperparathyroidism. The calcimimetic AMG 073 increases...
Gespeichert in:
| Veröffentlicht in: | Kidney international 2003-01, Vol.63 (1), p.248-254 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 254 |
|---|---|
| container_issue | 1 |
| container_start_page | 248 |
| container_title | Kidney international |
| container_volume | 63 |
| creator | Lindberg, Jill S. Moe, Sharon M. Goodman, William G. Coburn, Jack W. Sprague, Stuart M. Liu, Wei Blaisdell, Peter W. Brenner, Robert M. Turner, Stewart A. Martin, Kevin J. |
| description | The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.
A need exists for a therapy that lowers parathyroid hormone (PTH) without increasing calcium x phosphorus in patients with secondary hyperparathyroidism. The calcimimetic AMG 073 increases the sensitivity of the parathyroid calcium-sensing receptor to extracellular calcium, thereby reducing PTH secretion. Consequently, AMG 073 may provide a novel therapy for secondary hyperparathyroidism.
Seventy-eight hemodialysis patients with secondary hyperparathyroidism were enrolled into this 18-week, double-blind, randomized, placebo-controlled, dose titration study. Daily oral AMG 073 doses were administered to determine the effect on PTH, serum calcium, phosphorus, and calcium x phosphorus.
The mean baseline PTH was similar in patients administered AMG 073 or placebo (632 ± 280.1 pg/mL vs. 637 ± 455.9 pg/mL, respectively). PTH decreased by 26.0% in the AMG 073-treated group, compared with an increase of 22.0% in the placebo group (P < 0.001). A greater proportion in the AMG 073 group (38%) had a decrease in PTH ≥30%, compared with the placebo group (8%) (P = 0.001). Decreases in PTH were independent of baseline vitamin D usage. Patients receiving AMG 073 had an 11.9% decrease in calcium x phosphorus compared with a 10.9% increase in the placebo group (P < 0.001). Use of vitamin D sterols, as well as both calcium and noncalcium-containing phosphate binders. were similar between treatment groups. Administration of AMG 073 was safe and well tolerated in this 18-week study.
The calcimimetic AMG 073 decreases both PTH and calcium x phosphorus levels in hemodialysis patients with secondary hyperparathyroidism. |
| doi_str_mv | 10.1046/j.1523-1755.2003.00720.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_210109230</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0085253815488660</els_id><sourcerecordid>984958961</sourcerecordid><originalsourceid>FETCH-LOGICAL-c565t-ac89afaea94cfcb4ece6176c20aa62e6c3d0834bd2c24d8e2141f7b7c61dab5a3</originalsourceid><addsrcrecordid>eNqFkEtv1DAURi0EotPCTwBZSCwzXD_yWpYKWqQiNmVtOdc3ikfNAztBM_8eh4xadiwsy_rOd311GOMC9gJ08emwF7lUmSjzfC8B1B6glLA_vmC7p-Al2wFUeSZzVV2wyxgPkN61gtfsQkhdyrKGHRseOuJoH9H3vqfZI7_-fsuhVDyQW5Ain2ywc3cKo3e8G0M_DsTt4LbS0vMjn7oxphOWyP3AI-E4OBtOvDtNFP6p-9i_Ya9a-xjp7fm-Yj-_fnm4ucvuf9x-u7m-zzAv8jmzWNW2tWRrjS02mpAKURYowdpCUoHKQaV04yRK7SqSQou2bEoshLNNbtUV-7DNncL4a6E4m8O4hCF9aaQAAbVUkKBqgzCMMQZqzRR8nzY3Aszq2RzMqtOsOs3q2fz1bI6p-v48f2l6cs_Fs9gEfDwDNiZTbbAD-vjM6VrVFazcu40b7LwEegJ0ArSoU_55yynZ-u0pmIieBiTnA-Fs3Oj_v-0fhfGnwA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>210109230</pqid></control><display><type>article</type><title>The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>ProQuest Central UK/Ireland</source><source>Alma/SFX Local Collection</source><creator>Lindberg, Jill S. ; Moe, Sharon M. ; Goodman, William G. ; Coburn, Jack W. ; Sprague, Stuart M. ; Liu, Wei ; Blaisdell, Peter W. ; Brenner, Robert M. ; Turner, Stewart A. ; Martin, Kevin J.</creator><creatorcontrib>Lindberg, Jill S. ; Moe, Sharon M. ; Goodman, William G. ; Coburn, Jack W. ; Sprague, Stuart M. ; Liu, Wei ; Blaisdell, Peter W. ; Brenner, Robert M. ; Turner, Stewart A. ; Martin, Kevin J.</creatorcontrib><description>The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.
A need exists for a therapy that lowers parathyroid hormone (PTH) without increasing calcium x phosphorus in patients with secondary hyperparathyroidism. The calcimimetic AMG 073 increases the sensitivity of the parathyroid calcium-sensing receptor to extracellular calcium, thereby reducing PTH secretion. Consequently, AMG 073 may provide a novel therapy for secondary hyperparathyroidism.
Seventy-eight hemodialysis patients with secondary hyperparathyroidism were enrolled into this 18-week, double-blind, randomized, placebo-controlled, dose titration study. Daily oral AMG 073 doses were administered to determine the effect on PTH, serum calcium, phosphorus, and calcium x phosphorus.
The mean baseline PTH was similar in patients administered AMG 073 or placebo (632 ± 280.1 pg/mL vs. 637 ± 455.9 pg/mL, respectively). PTH decreased by 26.0% in the AMG 073-treated group, compared with an increase of 22.0% in the placebo group (P < 0.001). A greater proportion in the AMG 073 group (38%) had a decrease in PTH ≥30%, compared with the placebo group (8%) (P = 0.001). Decreases in PTH were independent of baseline vitamin D usage. Patients receiving AMG 073 had an 11.9% decrease in calcium x phosphorus compared with a 10.9% increase in the placebo group (P < 0.001). Use of vitamin D sterols, as well as both calcium and noncalcium-containing phosphate binders. were similar between treatment groups. Administration of AMG 073 was safe and well tolerated in this 18-week study.
The calcimimetic AMG 073 decreases both PTH and calcium x phosphorus levels in hemodialysis patients with secondary hyperparathyroidism.</description><identifier>ISSN: 0085-2538</identifier><identifier>EISSN: 1523-1755</identifier><identifier>DOI: 10.1046/j.1523-1755.2003.00720.x</identifier><identifier>PMID: 12472790</identifier><identifier>CODEN: KDYIA5</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adult ; Aged ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Biological and medical sciences ; calcimimetic ; Calcitriol - administration & dosage ; Calcium - blood ; Calcium Channel Agonists - administration & dosage ; calcium x phosphorus ; calcium-sensing receptor ; Cinacalcet Hydrochloride ; Emergency and intensive care: renal failure. Dialysis management ; end-stage renal disease ; Female ; General and cellular metabolism. Vitamins ; Humans ; Hyperparathyroidism, Secondary - blood ; Hyperparathyroidism, Secondary - drug therapy ; Intensive care medicine ; Kidney Failure, Chronic - complications ; Kidney Failure, Chronic - therapy ; Male ; Medical sciences ; Middle Aged ; Naphthalenes - administration & dosage ; Naphthalenes - adverse effects ; parathyroid hormone ; Parathyroid Hormone - blood ; Pharmacology. Drug treatments ; Phosphorus - blood ; Renal Dialysis ; secondary hyperparathyroidism ; Titrimetry</subject><ispartof>Kidney international, 2003-01, Vol.63 (1), p.248-254</ispartof><rights>2003 International Society of Nephrology</rights><rights>2003 INIST-CNRS</rights><rights>Copyright Nature Publishing Group Jan 2003</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c565t-ac89afaea94cfcb4ece6176c20aa62e6c3d0834bd2c24d8e2141f7b7c61dab5a3</citedby><cites>FETCH-LOGICAL-c565t-ac89afaea94cfcb4ece6176c20aa62e6c3d0834bd2c24d8e2141f7b7c61dab5a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/210109230?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,4024,27923,27924,27925,64385,64389,72469</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14939800$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12472790$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lindberg, Jill S.</creatorcontrib><creatorcontrib>Moe, Sharon M.</creatorcontrib><creatorcontrib>Goodman, William G.</creatorcontrib><creatorcontrib>Coburn, Jack W.</creatorcontrib><creatorcontrib>Sprague, Stuart M.</creatorcontrib><creatorcontrib>Liu, Wei</creatorcontrib><creatorcontrib>Blaisdell, Peter W.</creatorcontrib><creatorcontrib>Brenner, Robert M.</creatorcontrib><creatorcontrib>Turner, Stewart A.</creatorcontrib><creatorcontrib>Martin, Kevin J.</creatorcontrib><title>The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism</title><title>Kidney international</title><addtitle>Kidney Int</addtitle><description>The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.
A need exists for a therapy that lowers parathyroid hormone (PTH) without increasing calcium x phosphorus in patients with secondary hyperparathyroidism. The calcimimetic AMG 073 increases the sensitivity of the parathyroid calcium-sensing receptor to extracellular calcium, thereby reducing PTH secretion. Consequently, AMG 073 may provide a novel therapy for secondary hyperparathyroidism.
Seventy-eight hemodialysis patients with secondary hyperparathyroidism were enrolled into this 18-week, double-blind, randomized, placebo-controlled, dose titration study. Daily oral AMG 073 doses were administered to determine the effect on PTH, serum calcium, phosphorus, and calcium x phosphorus.
The mean baseline PTH was similar in patients administered AMG 073 or placebo (632 ± 280.1 pg/mL vs. 637 ± 455.9 pg/mL, respectively). PTH decreased by 26.0% in the AMG 073-treated group, compared with an increase of 22.0% in the placebo group (P < 0.001). A greater proportion in the AMG 073 group (38%) had a decrease in PTH ≥30%, compared with the placebo group (8%) (P = 0.001). Decreases in PTH were independent of baseline vitamin D usage. Patients receiving AMG 073 had an 11.9% decrease in calcium x phosphorus compared with a 10.9% increase in the placebo group (P < 0.001). Use of vitamin D sterols, as well as both calcium and noncalcium-containing phosphate binders. were similar between treatment groups. Administration of AMG 073 was safe and well tolerated in this 18-week study.
The calcimimetic AMG 073 decreases both PTH and calcium x phosphorus levels in hemodialysis patients with secondary hyperparathyroidism.</description><subject>Adult</subject><subject>Aged</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Biological and medical sciences</subject><subject>calcimimetic</subject><subject>Calcitriol - administration & dosage</subject><subject>Calcium - blood</subject><subject>Calcium Channel Agonists - administration & dosage</subject><subject>calcium x phosphorus</subject><subject>calcium-sensing receptor</subject><subject>Cinacalcet Hydrochloride</subject><subject>Emergency and intensive care: renal failure. Dialysis management</subject><subject>end-stage renal disease</subject><subject>Female</subject><subject>General and cellular metabolism. Vitamins</subject><subject>Humans</subject><subject>Hyperparathyroidism, Secondary - blood</subject><subject>Hyperparathyroidism, Secondary - drug therapy</subject><subject>Intensive care medicine</subject><subject>Kidney Failure, Chronic - complications</subject><subject>Kidney Failure, Chronic - therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Naphthalenes - administration & dosage</subject><subject>Naphthalenes - adverse effects</subject><subject>parathyroid hormone</subject><subject>Parathyroid Hormone - blood</subject><subject>Pharmacology. Drug treatments</subject><subject>Phosphorus - blood</subject><subject>Renal Dialysis</subject><subject>secondary hyperparathyroidism</subject><subject>Titrimetry</subject><issn>0085-2538</issn><issn>1523-1755</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFkEtv1DAURi0EotPCTwBZSCwzXD_yWpYKWqQiNmVtOdc3ikfNAztBM_8eh4xadiwsy_rOd311GOMC9gJ08emwF7lUmSjzfC8B1B6glLA_vmC7p-Al2wFUeSZzVV2wyxgPkN61gtfsQkhdyrKGHRseOuJoH9H3vqfZI7_-fsuhVDyQW5Ain2ywc3cKo3e8G0M_DsTt4LbS0vMjn7oxphOWyP3AI-E4OBtOvDtNFP6p-9i_Ya9a-xjp7fm-Yj-_fnm4ucvuf9x-u7m-zzAv8jmzWNW2tWRrjS02mpAKURYowdpCUoHKQaV04yRK7SqSQou2bEoshLNNbtUV-7DNncL4a6E4m8O4hCF9aaQAAbVUkKBqgzCMMQZqzRR8nzY3Aszq2RzMqtOsOs3q2fz1bI6p-v48f2l6cs_Fs9gEfDwDNiZTbbAD-vjM6VrVFazcu40b7LwEegJ0ArSoU_55yynZ-u0pmIieBiTnA-Fs3Oj_v-0fhfGnwA</recordid><startdate>200301</startdate><enddate>200301</enddate><creator>Lindberg, Jill S.</creator><creator>Moe, Sharon M.</creator><creator>Goodman, William G.</creator><creator>Coburn, Jack W.</creator><creator>Sprague, Stuart M.</creator><creator>Liu, Wei</creator><creator>Blaisdell, Peter W.</creator><creator>Brenner, Robert M.</creator><creator>Turner, Stewart A.</creator><creator>Martin, Kevin J.</creator><general>Elsevier Inc</general><general>Nature Publishing</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope></search><sort><creationdate>200301</creationdate><title>The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism</title><author>Lindberg, Jill S. ; Moe, Sharon M. ; Goodman, William G. ; Coburn, Jack W. ; Sprague, Stuart M. ; Liu, Wei ; Blaisdell, Peter W. ; Brenner, Robert M. ; Turner, Stewart A. ; Martin, Kevin J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c565t-ac89afaea94cfcb4ece6176c20aa62e6c3d0834bd2c24d8e2141f7b7c61dab5a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Biological and medical sciences</topic><topic>calcimimetic</topic><topic>Calcitriol - administration & dosage</topic><topic>Calcium - blood</topic><topic>Calcium Channel Agonists - administration & dosage</topic><topic>calcium x phosphorus</topic><topic>calcium-sensing receptor</topic><topic>Cinacalcet Hydrochloride</topic><topic>Emergency and intensive care: renal failure. Dialysis management</topic><topic>end-stage renal disease</topic><topic>Female</topic><topic>General and cellular metabolism. Vitamins</topic><topic>Humans</topic><topic>Hyperparathyroidism, Secondary - blood</topic><topic>Hyperparathyroidism, Secondary - drug therapy</topic><topic>Intensive care medicine</topic><topic>Kidney Failure, Chronic - complications</topic><topic>Kidney Failure, Chronic - therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Naphthalenes - administration & dosage</topic><topic>Naphthalenes - adverse effects</topic><topic>parathyroid hormone</topic><topic>Parathyroid Hormone - blood</topic><topic>Pharmacology. Drug treatments</topic><topic>Phosphorus - blood</topic><topic>Renal Dialysis</topic><topic>secondary hyperparathyroidism</topic><topic>Titrimetry</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lindberg, Jill S.</creatorcontrib><creatorcontrib>Moe, Sharon M.</creatorcontrib><creatorcontrib>Goodman, William G.</creatorcontrib><creatorcontrib>Coburn, Jack W.</creatorcontrib><creatorcontrib>Sprague, Stuart M.</creatorcontrib><creatorcontrib>Liu, Wei</creatorcontrib><creatorcontrib>Blaisdell, Peter W.</creatorcontrib><creatorcontrib>Brenner, Robert M.</creatorcontrib><creatorcontrib>Turner, Stewart A.</creatorcontrib><creatorcontrib>Martin, Kevin J.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>Kidney international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lindberg, Jill S.</au><au>Moe, Sharon M.</au><au>Goodman, William G.</au><au>Coburn, Jack W.</au><au>Sprague, Stuart M.</au><au>Liu, Wei</au><au>Blaisdell, Peter W.</au><au>Brenner, Robert M.</au><au>Turner, Stewart A.</au><au>Martin, Kevin J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism</atitle><jtitle>Kidney international</jtitle><addtitle>Kidney Int</addtitle><date>2003-01</date><risdate>2003</risdate><volume>63</volume><issue>1</issue><spage>248</spage><epage>254</epage><pages>248-254</pages><issn>0085-2538</issn><eissn>1523-1755</eissn><coden>KDYIA5</coden><abstract>The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.
A need exists for a therapy that lowers parathyroid hormone (PTH) without increasing calcium x phosphorus in patients with secondary hyperparathyroidism. The calcimimetic AMG 073 increases the sensitivity of the parathyroid calcium-sensing receptor to extracellular calcium, thereby reducing PTH secretion. Consequently, AMG 073 may provide a novel therapy for secondary hyperparathyroidism.
Seventy-eight hemodialysis patients with secondary hyperparathyroidism were enrolled into this 18-week, double-blind, randomized, placebo-controlled, dose titration study. Daily oral AMG 073 doses were administered to determine the effect on PTH, serum calcium, phosphorus, and calcium x phosphorus.
The mean baseline PTH was similar in patients administered AMG 073 or placebo (632 ± 280.1 pg/mL vs. 637 ± 455.9 pg/mL, respectively). PTH decreased by 26.0% in the AMG 073-treated group, compared with an increase of 22.0% in the placebo group (P < 0.001). A greater proportion in the AMG 073 group (38%) had a decrease in PTH ≥30%, compared with the placebo group (8%) (P = 0.001). Decreases in PTH were independent of baseline vitamin D usage. Patients receiving AMG 073 had an 11.9% decrease in calcium x phosphorus compared with a 10.9% increase in the placebo group (P < 0.001). Use of vitamin D sterols, as well as both calcium and noncalcium-containing phosphate binders. were similar between treatment groups. Administration of AMG 073 was safe and well tolerated in this 18-week study.
The calcimimetic AMG 073 decreases both PTH and calcium x phosphorus levels in hemodialysis patients with secondary hyperparathyroidism.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>12472790</pmid><doi>10.1046/j.1523-1755.2003.00720.x</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0085-2538 |
| ispartof | Kidney international, 2003-01, Vol.63 (1), p.248-254 |
| issn | 0085-2538 1523-1755 |
| language | eng |
| recordid | cdi_proquest_journals_210109230 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; ProQuest Central UK/Ireland; Alma/SFX Local Collection |
| subjects | Adult Aged Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Biological and medical sciences calcimimetic Calcitriol - administration & dosage Calcium - blood Calcium Channel Agonists - administration & dosage calcium x phosphorus calcium-sensing receptor Cinacalcet Hydrochloride Emergency and intensive care: renal failure. Dialysis management end-stage renal disease Female General and cellular metabolism. Vitamins Humans Hyperparathyroidism, Secondary - blood Hyperparathyroidism, Secondary - drug therapy Intensive care medicine Kidney Failure, Chronic - complications Kidney Failure, Chronic - therapy Male Medical sciences Middle Aged Naphthalenes - administration & dosage Naphthalenes - adverse effects parathyroid hormone Parathyroid Hormone - blood Pharmacology. Drug treatments Phosphorus - blood Renal Dialysis secondary hyperparathyroidism Titrimetry |
| title | The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T18%3A55%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20calcimimetic%20AMG%20073%20reduces%20parathyroid%20hormone%20and%20calcium%20x%20phosphorus%20in%20secondary%20hyperparathyroidism&rft.jtitle=Kidney%20international&rft.au=Lindberg,%20Jill%20S.&rft.date=2003-01&rft.volume=63&rft.issue=1&rft.spage=248&rft.epage=254&rft.pages=248-254&rft.issn=0085-2538&rft.eissn=1523-1755&rft.coden=KDYIA5&rft_id=info:doi/10.1046/j.1523-1755.2003.00720.x&rft_dat=%3Cproquest_cross%3E984958961%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=210109230&rft_id=info:pmid/12472790&rft_els_id=S0085253815488660&rfr_iscdi=true |